Literature DB >> 31342766

Emergency Department Visits for Psychotropic-Related Adverse Drug Events in Older Adults With Alzheimer Disease, 2013-2014.

Aryana Sepassi1, Jonathan H Watanabe1.   

Abstract

Background: More than 1.3 million emergency department visits have been associated with adverse drug events (ADEs) in older adults. Increasing Alzheimer's disease (AD) prevalence in the geriatric population poses an additive risk of ADEs because of the array of psychotropic medications prescribed for AD patients. Scant research has been conducted at a nationwide level on psychotropic-related ADEs in this population. Objective: This study aimed to determine the incidence and economic burden of psychotropic ADEs in the geriatric AD population compared with the non-AD geriatric population.
Methods: A retrospective analysis was conducted of geriatric AD patients who visited the ED in 2013 with a psychotropic-related ADE to determine the incidence and resource utilization of these events. The relationship between presence of AD and an ADE was analyzed using multiple logistic regression.
Results: There were 427 969 Alzheimer's ED visits compared with 20 492 554 ED visits without. Of the AD cases, 1.04% were associated with at least 1 adverse event. AD cases more frequently were admitted as inpatients (64.90% vs 34.92%, P < 0.01). Common drug classes associated with AD-related ADEs were benzodiazepines, antipsychotics, and autonomic nervous system-affecting agents (adrenergic agonists, antimuscarinic agents, anticholinergic agents). There was a significantly higher likelihood for Alzheimer's cases to experience any psychotropic-related adverse event (OR = 1.66; 95% CI = 1.20, 1.82). Conclusion and Relevance: Alzheimer's patients more frequently experienced psychotropic-related adverse events and related adverse outcomes than older adults without Alzheimer's. Application of these findings should be implemented in protocol development to reduce future psychotropic-related adverse outcomes for this population.

Entities:  

Keywords:  ADE; Alzheimer’s; HCUP; adverse drug events; geriatric; psychiatric; psychotropic

Mesh:

Substances:

Year:  2019        PMID: 31342766     DOI: 10.1177/1060028019866927

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  Deprescribing Antipsychotics Based on Real-World Evidence to Inform Clinical Practice: Safety Considerations in Managing Older Adults with Dementia.

Authors:  Stephanie Hsieh; Jing Yuan; Z Kevin Lu; Minghui Li
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

Review 2.  Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer's Disease: Insights From Preclinical Models, Clinical Data, and Future Directions.

Authors:  Amalie Clement; Ove Wiborg; Ayodeji A Asuni
Journal:  Front Aging Neurosci       Date:  2020-03-06       Impact factor: 5.750

3.  Analysis of Benzodiazepine Prescription Practices in Elderly Appalachians with Dementia via the Appalachian Informatics Platform: Longitudinal Study.

Authors:  Niharika Bhardwaj; Alfred A Cecchetti; Usha Murughiyan; Shirley Neitch
Journal:  JMIR Med Inform       Date:  2020-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.